Answers are grounded in this paper and cite their sources.
Background: Glioblastoma (GBM) exhibits marked dependence on ribonucleotide reductase regulatory subunit M2 (RRM2) to cope with endogenous replication stress. Pectolinarigenin (PECT) suppresses GBM partly by inhibiting RRM2, yet the upstream mechanism conveying PECT’s effect to the RRM2 promoter remains undefined. Methods: Bioinformatic prediction (PROMO, SwissRegulon, JASPAR, TFsearch) and TCGA/GTEx analyses (GEPIA2) were used to identify and characterize candidate regulators of RRM2. U251 and U87 GBM cells were analyzed by DCFH-DA staining, MTT assay, qRT-PCR, and Western blotting with siRNA knockdown, overexpression, NAC rescue, and dual-luciferase reporter assays using wild-type and binding-site-mutant RRM2 promoter reporters. Results: PECT-induced ROS accumulation and ROS-dependent cytotoxicity in GBM cells. E2F1 was upregulated in GBM, correlated with RRM2 expression (R = 0.71), and predicted poor overall survival (HR = 1.5, log-rank p = 0.028); E2F1 knockdown reduced RRM2 at both mRNA and protein levels. PECT dose-dependently suppressed E2F1 and RRM2, with E2F1 mRNA declining prior to RRM2, and NAC reversed PECT-mediated E2F1 suppression, demonstrating ROS dependence. A predicted GC-rich E2F1-response element (5′-CGGGCGCGAGA−3′) in the RRM2 promoter was required for E2F1-mediated transactivation and for PECT-induced repression, and ectopic E2F1 partially rescued GBM cells from PECT-induced cytotoxicity. Conclusions: Taken together, our data support a model in which PECT suppresses RRM2 transcription through ROS-dependent downregulation of its upstream activator E2F1, identifying the ROS–E2F1–RRM2 axis as a candidate for therapeutic targeting in GBM.
No takes yet. Share an insight, caveat, or question.
Haiping et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: